Interestingly, ~15–20% of BRAFV600E metastatic CRC harbors MSI17, and these patients also showed better and more durable responses to BRAF/MAPK pathway inhibition than patients who are MSS in prior clinical trials of BRAF/MEK/EGFR inhibition, despite receiving targeted BRAF-directed therapy only. This evidence concerns the gene BRAF and colorectal carcinoma.